Search CommunityWalk:


FASgen, Inc.

UMB Research Park, Building One, 800 W. Baltimore St., Suite 150
Baltimore, MD 21201, USA

Category: Diagnostic/Imaging; Research Services & Supplies

Used in the following map:

Maryland Biotech Industry Map

FASgen, Inc. is a drug development company that focused on development and commercialization of small molecule therapeutics and diagnostics using fatty acid biosynthesis targets. It was formed in 2000 by James D. Dick, Frank P. Kuhajda, Albert H. Owens and Craig A. Townsend.

FASgen has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. Its product pipeline is focused on the therapeutic areas of cancer, tuberculosis, obesity and diabetes. The company's product portfolio includes: FAS-detect(TM) IHC, a monoclonal antibody with specificity for Fatty Acid Synthase indicated for the treatment of a variety of common human carcinomas; and FAS-detect(TM) ELISA, an enzyme-linked immunosorbent assay used to detect soluble FAS in human serum.

FASgen has agreements with Centocor, Inc., The National Cancer Institute, The National Institutes of Health, etc.